Adalimumab
ArticlesRefrigerated StorageLactation Safety InformationNew Medicines · Published , updatedArticles
Safety in lactation: Drugs for chronic bowel disorders
Additional information relating to breastfeeding To be used in conjunction with individual drug entries for specific information and guidance. Aminosalicylates for chronic bowel disorders Mesalazine… Adalimumab Azathioprine Balsalazide Beclometasone Budesonide Ciclosporin Gastrointestinal disorders Golimumab Hydrocortisone Infliximab Mercaptopurine Mesalazine Methotrexate Obstetrics and gynaecology Paediatrics and neonates Prednisolone Safety in Breastfeeding Sulfasalazine Teduglutide Ustekinumab VedolizumabRMOC briefing on adalimumab – July 2019
This sixth briefing paper is provided through the RMOC system. It is the July edition of a series of briefings on best value biological medicines.… Adalimumab Biosimilars RMOC recommendations and resourcesAdalimumab: procurement and reference pricing FAQ
See below for an FAQ document produced through the RMOC system on adalimumab. It includes detail on the procurement process, its outcome and implementation. Adalimumab Biosimilars RMOC recommendations and resourcesUpdate on development of biosimilar versions of adalimumab with particular focus on excipients and injection site reactions
An overview of the five versions of adalimumab currently available in the UK. These article focuses on the differences in excipients and in particular the… Adalimumab Excipients TrustsSafety in Lactation: Systemic preparations for eczema and psoriasis
Drugs used orally or parenterally for severe eczema and psoriasis have a varied pharmacology, mainly either modifying the immune response to the disease or modifying… Acitretin Adalimumab Alitretinoin Azathioprine Ciclosporin Etanercept Infliximab Methotrexate UstekinumabRMOC briefing on adalimumab – December
This fifth briefing paper is provided through the RMOC system. It is the December edition of a series of briefings on best value biological medicines.… Adalimumab Biosimilars RMOC recommendations and resourcesAdalimumab toolkit for commissioners and providers
The Commissioning Support Units have produced an interactive toolkit and associated resources on behalf of (and approved by) the Regional Medicines Optimisation Committees. These resources… Adalimumab Biosimilars RMOC recommendations and resourcesAdalimumab resources to use with patients
These resources have been put together by the NHS England Pharmacy Communications team. They are designed for professionals to use with patients to support introduction… Adalimumab Biosimilars RMOC recommendations and resourcesRMOC briefing on adalimumab – July 2018
This third briefing paper is provided through the RMOC system. It forms the July edition of a series of briefings on best value biological medicines. … Adalimumab Biosimilars RMOC recommendations and resourcesRefrigerated Storage
Humira
AbbVieIn the event of an inadvertent temperature excursion the following data may be used:
A single Humira pre-filled syringe or pre-filled pen may be stored at temperatures up to a maximum of 25°C for a period of up to 14 days. The syringe or pen must be protected from light, and discarded if not used within the 14 -day period
Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk
For information outside of this excursion, contact AbbVie Ltd directly. Refer to the current BNF for company contact details.
Amgevita
Amgen LtdIn the event of an inadvertent temperature excursion the following data may be used:
The pre-filled syringe or pre-filled pen may be stored at temperatures up to a maximum of 25°C for a period of up to 14 days. The pre-filled syringe or pre-filled pen must be protected from light, and discarded if not used within the 14-day period.
Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk
Imraldi
BiogenOnce exposed to temperatures up to 25°C, the syringe or pen must be used within 28 days or discarded, even if it is returned to the refrigerator.
You should record the date when the syringe or pen is first removed from refrigerator, and the date after which it should be discarded.
Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk
Hyrimoz
SandozIn the event of an inadvertent temperature excursion the following data may be used:
A single Hyrimoz pre-filled syringe / pre-filled pen may be stored at temperatures up to a maximum of 25°C for a period of up to 21 days. The pre-filled syringe / pre-filled pen must be protected from light, and discarded if not used within the 21-day period.
The manufacturers have stated that they will deal with temperature excursions on a case by case basis to ensure the most up to date information is provided each time. Refer to the current BNF for company contact details.
Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk
Storage at ambient temperature: not provided by manufacturer.
Do not freeze. Keep the pre-filled syringe / pre-filled pen in the outer carton in order to protect from light. Do not shake.
Hulio
MylanIn the event of an inadvertent temperature excursion the following data may be used:
A single Hulio pre-filled syringe or pre-filled pen may be stored at temperatures up to a maximum of 25°C for a period of up to 14 days. The syringe or pen must be protected from light, and discarded if not used within the 14 -day period.
Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk
For information outside of this excursion, contact Mylan directly. Refer to the current BNF for company contact details.